NEW YORK, May 9 (Reuters) – A consortium comprising Elliott Investment Management, Patient Square Capital and Veritas Capital is nearing a deal to accumulate Syneos Health Inc (SYNH.O), a supplier of medical analysis to drug builders with a market worth of $4 billion, folks acquainted with the matter stated.

While the worth that the consortium is paying for Syneos couldn’t be discovered, the corporate’s shares have risen over 20% since Reuters first reported on Feb 27 that Syneos was exploring a potential sale.

The sources requested anonymity as a result of the matter is confidential. Syneos, Elliott, and Veritas didn’t instantly reply to requests for remark. Patient Square declined to remark.

Bloomberg News first reported the information of the funding consortium’s talks with Syneos. Shares of Syneos had been up about 19% in after-market buying and selling.

Based in Morrisville, North Carolina, Syneos helps pharmaceutical corporations with medical trials and to market their medicine.

Syneos, which carries a debt pile of almost $3 billion, was created in 2017 by INC Research Holdings Inc’s acquisition of inVentiv Health Inc for $7.4 billion, together with debt.

INC Research modified its title to Syneos in 2018. The deal buoyed the corporate by giving it scale and broadening its choices for the outsourcing of the event and commercialization of medicine.

Syneos reported a complete backlog for contracts of $6.8 billion as of the tip of 2022, down from $7.5 billion as of the tip of 2021.

There has been a wave of consolidation amongst contract analysis organizations in search of to decrease prices, amass extra medical trial information and win clients.

Most just lately, Thermo Fisher Scientific Inc (TMO.N) acquired PPD Inc for $17.4 billion and Icon Plc (ICLR.O) took over PRA Health Sciences Inc for $12 billion.

Reporting by Anirban Sen in New York

Our Standards: The Thomson Reuters Trust Principles.